Original language | English |
---|---|
Journal | PLoS Medicine |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - May 2010 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: PLoS Medicine, Vol. 7, No. 5, 05.2010.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Which new approaches to tackling neglected tropical diseases show promise?
AU - Spiegel, Jerry M.
AU - Dharamsi, Shafik
AU - Wasan, Kishor M.
AU - Yassi, Annalee
AU - Singer, Burton
AU - Hotez, Peter J.
AU - Hanson, Christy
AU - Bundy, Donald A.P.
N1 - Funding Information: KW has received funding provided by the Consortium for Parasitic Drug Development via the Bill/Melinda Gates Foundation) toward the development of a safe and efficacious oral AmB formulation, but has no competing interests since he is not an employee of iCo Therapeutics Inc., the company that has licensed the technology from UBC and is not working with any other companies that are developing Amphotericin B products. PJH is partially supported by the Bill & Melinda Gates Foundation, Seattle, Washington, United States of America, through Human Hookworm Vaccine Initiative of the Albert B. Sabin Vaccine Institute, Washington, District of Columbia, United States of America. He is an inventor on an international patent application (PCT/US02/33106; filed November 11, 2002) entitled “Hookworm vaccine.” Additional provisional patents have been filed for hookworm and schistosomiasis vaccines. The patent was filed in the United States, Brazil, India, China, and Mexico. The patents belong to The George Washington University, with an exclusive license to the Human Hookworm Vaccine Initiative of the Albert B. Sabin Vaccine Institute, a nonprofit (501c3) organization devoted to increasing the use of vaccines worldwide. Because hookworm and schistosomiasis are neglected diseases afflicting the poorest of the poor in developing countries, these vaccines have no anticipated commercial value or income generating potential. The rationale for filing a patent is to ensure that the vaccine is developed for those who need it in developing countries, and to encourage vaccine manufacturers in developing countries to work with the Albert B. Sabin Vaccine Institute for manufacture of the hookworm vaccine. PJH is Chair of the Department of MITM at GWU and is President of the Albert B. Sabin Vaccine Institute. The other authors declare no competing interests.
PY - 2010/5
Y1 - 2010/5
UR - http://www.scopus.com/inward/record.url?scp=77953237263&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1000255
DO - 10.1371/journal.pmed.1000255
M3 - Article
C2 - 20502599
AN - SCOPUS:77953237263
SN - 1549-1277
VL - 7
JO - PLoS Medicine
JF - PLoS Medicine
IS - 5
ER -